Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) EBT Margin (2020 - 2025)

Historic EBT Margin for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q2 2025 value amounting to 2115100.0%.

  • Barinthus Biotherapeutics' EBT Margin changed N/A to 2115100.0% in Q2 2025 from the same period last year, while for Sep 2025 it was 23994.01%, marking a year-over-year decrease of 236015400.0%. This contributed to the annual value of 409.03% for FY2024, which is 91323700.0% up from last year.
  • Barinthus Biotherapeutics' EBT Margin amounted to 2115100.0% in Q2 2025.
  • Barinthus Biotherapeutics' EBT Margin's 5-year high stood at 1668600.0% during Q4 2021, with a 5-year trough of 2115100.0% in Q2 2025.
  • Its 5-year average for EBT Margin is 41981.97%, with a median of 4004.06% in 2023.
  • In the last 5 years, Barinthus Biotherapeutics' EBT Margin skyrocketed by 2000000000bps in 2021 and then tumbled by 2000000000bps in 2022.
  • Barinthus Biotherapeutics' EBT Margin (Quarter) stood at 1668600.0% in 2021, then plummeted by -100bps to 359.02% in 2022, then crashed by -1982bps to 7473.05% in 2023, then surged by 99bps to 54.33% in 2024, then crashed by -3893276bps to 2115100.0% in 2025.
  • Its EBT Margin was 2115100.0% in Q2 2025, compared to 6227.85% in Q1 2025 and 54.33% in Q3 2024.